Effect of Anlotinib on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

This randomized clinical trial examines the efficacy of anlotinib compared with placebo as a third-line or further therapy on overall survival of adult patients with advanced non–small cell lung cancer.

Read the full article here

Related Articles